Protagonist Therapeutics (PTGX) stock has attracted fresh attention recently, supported by strong trailing total returns and new interest in its clinical pipeline. This has prompted investors to reassess how current pricing lines up with underlying fundamentals.

At a share price of $121.63, Protagonist Therapeutics has shown strong momentum, with a 30 day share price return of 22.17% and a year to date share price return of 39.52%. Longer term total shareholder returns have been very large over three years and robust over five years.

If Protagonist Therapeutics has put high growth biotech on your radar, it may be worth broadening your watchlist and checking out 41 healthcare AI stocks

With Protagonist Therapeutics now valued at about $7.8b and trading slightly above the average analyst price target, the key question is whether the stock still offers upside or whether the market is already fully pricing in its future growth.

Discounted Cash Flow suggests significant upside

On Simply Wall St's DCF model, Protagonist Therapeutics has an estimated future cash flow value of $371.09 per share, compared with the last close of $121.63. That gap points to a large implied discount at the current share price.

The SWS DCF model projects future cash flows for Protagonist Therapeutics and then discounts those cash flows back to today using a required rate of return. This approach aims to capture what the business could be worth based on its own cash generation rather than short term market sentiment.

For a clinical stage biotech that is currently loss making, a cash flow based view can be particularly useful, because traditional valuation ratios can be hard to interpret when earnings are still negative. The model will be sensitive to assumptions around the ramp up of revenue, margins and the timing of potential profitability, which are key questions for a pipeline that includes Rusfertide, Icotyde and several early stage candidates.

Result: DCF Fair value of $371.09 (UNDERVALUED)

However, Protagonist Therapeutics is still loss making, with a reported net loss of US$114.711m and depends heavily on successful clinical outcomes across its pipeline.

Another view on Protagonist Therapeutics valuation

While the SWS DCF model points to a large gap between Protagonist Therapeutics' current share price and its estimated future cash flow value, a simple balance sheet lens tells a different story. The stock trades on a P/B of 11.9x compared with 2.6x for the broader US biotechs industry and 16x for direct peers.

That mix of cheaper than peers but much richer than the wider sector suggests investors are already paying a premium for Protagonist Therapeutics' pipeline, even if the DCF still signals room for upside. Which signal you trust more may come down to how comfortable you are with clinical and funding risk at this stage.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Protagonist Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 42 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Given the mix of enthusiasm and concern around Protagonist Therapeutics, it makes sense to move quickly, study the underlying data and test your own thesis. To weigh the upside against the downside in one place, take a close look at the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Protagonist Therapeutics?

If Protagonist Therapeutics has sharpened your focus on high conviction opportunities, do not stop here. Use the tools available and keep building a stronger watchlist.

• Target steady compounding by scanning companies built for resilience with the 72 resilient stocks with low risk scores.
• Hunt for potential bargains that combine quality and attractive pricing through the 42 high quality undervalued stocks.
• Spot potential future leaders before the crowd by checking the screener containing 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.